Conclusions
The severe inflammatory state
caused by Sars-CoV-2 infection leads to lung collapse, respiratory
difficulties due to fibrosis and death of the patient. The sudden
release of cytokines in the circulation, known as ”cytokine storm” (CS),
is a phenomenon that must be countered in order not to get scarring of
the lung tissue. To date, there are still no effective antivirals that
can prevent the evolution of this clinical picture and, pending better
solutions, it is good to avoid the patient’s death with the blocking of
inflammation and the dissolution of the fibrotic tissue formed. The goal
is to save the patient’s life. Correct management of the inflammatory /
immune status of the infected patient takes on a priority role. In the
third stage, the more serious one, the combined use of anti-inflammatory
drugs and pirfenidone can help avoid death from SARS-CoV-2. The use of
pirfenidone, for its good tolerability and safety, could be a winning
move. In addition, the combined use of multiple drugs allows a safe and
non-risky dosage compared to monotherapy and is certainly the most
effective and tolerable solution for managing the inflammatory and
fibrotic state.
MAIN STATEMENTS
I, the undersigned, Francesco Ferrara and any other author, declare
that:
We have no conflict of interest;
We have not received funding;
There are no sensitive data and no patients were recruited for this
study;
The document does not conflict with ethical legislation.
Regards
The authors